Quick Answer: CAR-T Therapy Hospitals in China, 2026
If you need CAR-T therapy, expect $89,000-$151,000 for a commercial NMPA-approved product in China — roughly 65-85% below US pricing ($500K-$699K) and 40-60% below Singapore ($280K-$350K). Eligible patients can reduce costs further through clinical trials ($30K-$80K). The five hospitals international patients choose most are PUMCH (Beijing) for complex hematologic cases, Fudan Cancer Hospital (Shanghai) for the highest CAR-T volume in Asia, Ruijin Hospital (Shanghai) for hematology leadership and trial access, Lu Daopei Hospital (Beijing) for blood-cancer specialization including multiple myeloma, and Peking University People's Hospital (Beijing) for aggressive lymphoma. All five have English-speaking international departments, accept remote case review, and issue visa invitation letters. The full journey — from records review to infusion — takes about 4-6 weeks in China, with most slots bookable 2-4 weeks after eligibility is confirmed.
1. CAR-T Therapy Cost in China vs Singapore, Thailand & US (2026)
CAR-T pricing in China has two tiers, which is why quotes for the same therapy can differ by 3-5x between patients.
| Access Route | 2026 Price (USD) | Best For |
|---|---|---|
| Commercial (NMPA-approved product) | $89K – $151K | Patients who want a specific approved product with no trial eligibility requirements |
| Clinical trial / sponsored access | $30K – $80K | Eligible patients willing to enroll in a hospital- or manufacturer-sponsored trial |
Country Comparison (CD19 / BCMA CAR-T, Hematologic Cancers)
| Country | Commercial Price (USD) | Notes |
|---|---|---|
| China | $89K – $151K | 7 NMPA-approved CAR-T products — the most of any country; satri-cel (solid tumor) also approved June 2026 |
| Singapore | $280K – $350K | Kymriah available; no domestic CAR-T manufacturing |
| Thailand | Not commercially approved | Trial access only; limited slots |
| United States | $500K – $699K | 6 FDA-approved products; highest list prices globally |
| Germany / EU | $320K – $400K | Approved products available; prices vary by country |
2026 estimates based on published data and patient-reported quotes. Travel, accommodation, and bridging chemotherapy are not included. Final cost depends on your specific case — always request a written itemized quote from the hospital's international department.
What's included in a typical quote: T-cell collection (apheresis), cell manufacturing, conditioning chemotherapy, the CAR-T infusion, 2-3 weeks of inpatient monitoring, and English-language discharge records. Most hospitals ask for a 30-50% deposit to lock the manufacturing slot.
2. Top 5 Hospitals for CAR-T Therapy in China
1. Peking Union Medical College Hospital (PUMCH) — Beijing
| Field | Detail |
|---|---|
| Official English name | Peking Union Medical College Hospital (PUMCH) |
| Specialties | Hematology, B-cell ALL, large B-cell lymphoma, cell therapy research |
| International patient services | Yes — International Medical Center, English-speaking coordinators, record translation, visa invitation letters within 48 hours of confirmed admission |
| Cost range (commercial CAR-T) | $110K – $151K |
| Waiting time | 2-4 weeks after eligibility confirmed |
| Why recommended | Among the first hospitals in Asia to run CAR-T trials; China's leading academic medical center for cell therapy; extensive published outcomes for B-ALL and large B-cell lymphoma |
2. Fudan Cancer Hospital (Fudan University Shanghai Cancer Center) — Shanghai
| Field | Detail |
|---|---|
| Official English name | Fudan University Shanghai Cancer Center (Fudan Cancer Hospital) |
| Specialties | B-cell lymphoma, follicular lymphoma, Claudin18.2 solid-tumor CAR-T (gastric) |
| International patient services | Yes — dedicated International Patient Center, English/Japanese/Korean/Arabic interpreters, airport pickup, 20+ international insurers for direct billing |
| Cost range (commercial CAR-T) | $95K – $140K |
| Waiting time | 2-3 weeks; typically the shortest slots among top centers |
| Why recommended | One of the highest-volume CAR-T programs in Asia with 800+ patients treated since 2019 and published 3-year follow-up data; exclusive access to the Claudin18.2 gastric cancer trial |
3. Shanghai Ruijin Hospital (Shanghai Jiao Tong University) — Shanghai
| Field | Detail |
|---|---|
| Official English name | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| Specialties | Hematology (#1 in China), CRS management, CD19 and BCMA CAR-T, autoimmune disease trials (SLE, MS) |
| International patient services | Yes — international affairs office, hotel booking, visa extensions, translation; initial evaluation within 5-7 working days |
| Cost range (commercial CAR-T) | $89K – $135K |
| Waiting time | 2-4 weeks after eligibility confirmed |
| Why recommended | One of the first institutions certified for commercial CAR-T in China; published outcomes on 500+ CAR-T patients; designated center for autoimmune CAR-T trials; on-site GMP-standard cell processing lab |
4. Lu Daopei Hospital — Beijing
| Field | Detail |
|---|---|
| Official English name | Lu Daopei Hospital |
| Specialties | Hematology-only (leukemia, lymphoma, multiple myeloma), BCMA-targeted CAR-T for myeloma |
| International patient services | Yes — patients from 12+ countries, English-speaking case managers, care coordination back to home country |
| Cost range (commercial CAR-T) | $100K – $145K |
| Waiting time | 2-4 weeks after eligibility confirmed |
| Why recommended | Founded by a pioneer of bone marrow transplantation in China; exclusive focus on blood cancers; multiple myeloma CAR-T outcomes reported at or above international benchmarks; strong track record with international follow-up |
5. Peking University People's Hospital — Beijing
| Field | Detail |
|---|---|
| Official English name | Peking University People's Hospital |
| Specialties | Relapsed/refractory DLBCL, bridge chemotherapy protocols, GPC3 liver cancer trial |
| International patient services | Yes — English-speaking coordinators, video consultation before travel, direct billing via Euro-Center and Global Medical Management |
| Cost range (commercial CAR-T) | $95K – $138K |
| Waiting time | 2-4 weeks after eligibility confirmed |
| Why recommended | One of the busiest CAR-T programs in northern China; developed a bridge chemotherapy protocol that controls aggressive lymphoma while cells are manufactured; high-volume DLBCL experience |
Not sure which CAR-T center fits your case? Send your pathology report, prior treatment history, and recent PET-CT or bone marrow biopsy — we route your case to the right oncology center and get a written plan back within 48 hours. Get a free hospital recommendation and cost estimate → Start Free Case Review (We reply within 24 hours · 100% confidential · No obligation).
3. Treatment Timeline: From First Contact to Infusion
| Phase | What Happens | Duration |
|---|---|---|
| 1. Records review | Send pathology report, treatment history, PET-CT/biopsy results; hospital confirms CAR-T candidacy | 1-3 days |
| 2. Treatment plan & quote | Written plan: product, cost estimate, trial options if eligible | 3-10 days |
| 3. Visa & booking | Hospital issues medical visa invitation letter (M visa); book flights to Beijing/Shanghai/Guangzhou | 1-2 weeks |
| 4. T-cell collection | Leukapheresis — blood drawn, T-cells separated, rest returned; no general anesthesia | 1-2 days |
| 5. Cell processing | Cells engineered in GMP lab; bridging chemo may be given to control disease | 10-14 days |
| 6. Conditioning + infusion | Short lymphodepleting chemo (3-5 days), then CAR-T infusion via IV (30 minutes) | 4-6 days |
| 7. Monitoring & discharge | Inpatient monitoring for CRS/neurotoxicity management; discharge with follow-up schedule | 2-3 weeks |
| 8. Remote follow-up | Blood tests and PET-CT at home hospital; results shared with Chinese team via telemedicine | Ongoing |
Total time in China: 4-6 weeks for most CAR-T patients. Plan accordingly.
4. Real Patient Examples
A lymphoma patient from the United Kingdom was told CAR-T was available on the NHS only after two prior treatment lines had failed, while his lymphoma was progressing. Fudan Cancer Hospital had a CAR-T slot within two weeks; the international team arranged the visa letter, nearby hotel, and an interpreter. The total cost was about £90,000 less than the private UK quote. Three months after infusion, his PET scan showed complete metabolic response.
A family from Singapore with a daughter who had relapsed acute lymphoblastic leukemia consulted hospitals in the US and Germany, where the earliest slots were 8-10 weeks out. PUMCH admitted her within 12 days. The doctors communicated with her home oncologist in Singapore throughout treatment. She is 18 months post-CAR-T with no evidence of disease.
Individual results vary. Outcomes depend on disease type, prior treatment, and eligibility. A doctor at the hospital will evaluate your case and recommend the appropriate treatment. More patient journeys: Maria's case in progress at Shanghai Ninth People's Hospital.
5. What Cancers Does CAR-T Treat in China?
| Cancer Type | CAR-T Target | NMPA Approved (China) | Trial Available |
|---|---|---|---|
| B-cell ALL (adult & pediatric) | CD19 | Yes | Yes |
| Diffuse large B-cell lymphoma (DLBCL) | CD19 | Yes | Yes |
| Follicular lymphoma (FL) | CD19 | Yes | Yes |
| Mantle cell lymphoma (MCL) | CD19 | Yes | Yes |
| Multiple myeloma | BCMA | Yes | Yes |
| Liver cancer (hepatocellular carcinoma) | GPC3 | Trial only | Yes — SYSUCC, Fudan |
| Gastric / pancreatic cancer | Claudin18.2 | Satri-cel approved (gastric/GEJ) | Yes — Fudan |
| SLE / autoimmune diseases | CD19 | Trial only | Yes — Ruijin, West China |
Clinical trial note: Trial participation means the therapy is not yet commercially approved. Screening criteria are strict, outcomes are uncertain, and international patients should confirm eligibility before committing to travel. Trial participation may reduce or eliminate product costs, but hospital fees still apply.
6. Frequently Asked Questions
Which hospitals in China offer CAR-T therapy to international patients?
PUMCH, Fudan Cancer Hospital, Ruijin Hospital, Lu Daopei Hospital, and Peking University People's Hospital — all with dedicated international departments, English-speaking staff, and visa support. For private Western-style care, SinoUnited Hospital (Shanghai) also runs a dedicated international CAR-T center at $130K-$165K.
How much does CAR-T therapy cost in China in 2026?
$89,000-$151,000 for commercial NMPA-approved products, or $30,000-$80,000 via clinical trials for eligible patients. That's 65-85% below US pricing and roughly 40-60% below Singapore. Final cost depends on product, hospital, and whether bridging chemotherapy is needed.
How long does CAR-T treatment take in China?
4-6 weeks on-site — apheresis (1-2 days), cell processing (10-14 days), conditioning chemo (3-5 days), infusion, then 2-3 weeks of monitoring. Slots are typically bookable 2-4 weeks after eligibility is confirmed.
Is CAR-T therapy in China safe?
Commercial products are NMPA-approved, and top centers manage CRS and neurotoxicity per international protocols with ICU support. JCI-accredited or NMPA-certified hospitals report outcomes comparable to international benchmarks for eligible patients.
Can international patients join CAR-T clinical trials in China?
Yes, especially for solid tumors (liver, gastric, pancreatic) and autoimmune diseases. Eligibility is strict, screening is not guaranteed, and outcomes are uncertain — but trial participation may reduce or eliminate product costs.
Get a Free Hospital Recommendation & Cost Estimate
Tell us your diagnosis and treatment history — we'll match you with 2-3 suitable CAR-T centers, get written commercial and trial quotes, and handle visa letters, airport pickup, and English-speaking coordination. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review